Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
105.10
(
0.00%
)
Bitcoin
68,788.00
(
-0.15%
)
News Focus
News Focus
Post# of 257268
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 123710

Wednesday, 08/03/2011 3:46:03 PM

Wednesday, August 03, 2011 3:46:03 PM

Post# of 257268
AMGN expects Teva to launch Neutroval (Neupogen FoB) in Nov 2013, but AMGN does not expect Teva to launch Neugranin (Neulasta FoB) in Nov 2013, according to AMGN’s 2Q11 CC. In other words, the settlement announced in #msg-65277106 ensures that Teva cannot launch Neugranin before Nov 2013, but it does not grant Teva a license to launch Neugranin in Nov 2013.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today